Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
PIONEER8 is a randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of semaglutide combined with insulin
Two major clinical trials are the basis for most of what's known about these medications' weight-management effects: STEP 1 (68-week randomized study, adults without diabetes): semaglutide 2.4 mg produced an average loss of roughly 15% of body weight, versus about 2.4% with placebo, alongside a reduced-calorie diet and increased physical activity
And if you went the other direction, drawing 40 units from a 5mg/ml vial, you would inject 2.0mg, double your intended dose
Frequently Asked Questions Explore Personalized Weight Loss Options Start with an online assessment to help a licensed clinician determine whether a prescription weight loss treatment, along with guided nutritional support, may be appropriate for you.
Industry involvement
:max_bytes(150000):strip_icc()/WhatstheDifferenceBetweenOzempicWegovyandMounjaro-illo-a8f5a23fe4914586b4488472fe15f112.png)
